Erasca (ERAS) News Today → “The Biggest Bubble of All Time” – Here’s What to Do. (From Chaikin Analytics) (Ad) Free ERAS Stock Alerts $1.86 -0.02 (-0.80%) (As of 12:16 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineErasca Announces Three Presentations at the 2024 ASCO Annual Meetingglobenewswire.com - April 24 at 4:05 PMInstitutional investors may adopt severe steps after Erasca, Inc.'s (NASDAQ:ERAS) latest 11% drop adds to a year lossesfinance.yahoo.com - April 16 at 8:43 AMErasca (NASDAQ: ERAS)fool.com - April 9 at 8:14 AMErasca’s Promising Naporafenib Data and Financial Stability Merit a Buy Ratingmarkets.businessinsider.com - April 3 at 10:50 AMErasca, Inc. (NASDAQ:ERAS) Short Interest Down 8.9% in Marchmarketbeat.com - April 2 at 9:24 PMThe Goldman Sachs Group Boosts Erasca (NASDAQ:ERAS) Price Target to $7.00marketbeat.com - April 2 at 1:57 PMErasca, Inc. (NASDAQ:ERAS) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - April 1 at 6:22 PMErasca, Inc. (ERAS) R&D Update Call and Q4 2023 Earnings Call Transcriptseekingalpha.com - March 31 at 12:14 PMErasca, Inc.: Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Resultsfinanznachrichten.de - March 29 at 3:20 PMErasca Inc (ERAS) Aligns with EPS Projections, Reveals Robust Balance Sheet and Key Clinical ...finance.yahoo.com - March 29 at 8:39 AMErasca’s Strong Clinical Data and Enhanced Financial Position Support Buy Ratingmarkets.businessinsider.com - March 29 at 2:51 AMAnalysts Offer Insights on Healthcare Companies: Celcuity (CELC) and Erasca (ERAS)markets.businessinsider.com - March 28 at 4:50 PMErasca to get $45M funding via private placementmsn.com - March 28 at 11:50 AMErasca Shares Climb After 4Q Loss Narrows, $45 Million Private Placementmarketwatch.com - March 28 at 11:50 AMERAS Stock Earnings: Erasca Beats EPS for Q4 2023investorplace.com - March 27 at 11:03 PMErasca Announces $45 Million Oversubscribed Private Placement Financingglobenewswire.com - March 27 at 8:30 PMErasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Resultsglobenewswire.com - March 27 at 4:01 PMOcugen hits a 52-week high after decision to lower quorum requirementmsn.com - March 21 at 4:45 PMERAS Mar 2024 2.000 putfinance.yahoo.com - February 27 at 8:35 PMERAS Mar 2024 2.500 callfinance.yahoo.com - February 17 at 9:39 AMErasca collaborates with Novartis on cancer therapy trialsmsn.com - February 15 at 3:05 PMErasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trialsfinance.yahoo.com - February 14 at 9:00 AMErasca, Inc. (NASDAQ:ERAS) Short Interest Updatemarketbeat.com - February 1 at 10:44 AMErasca to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conferencefinance.yahoo.com - February 1 at 8:17 AMIs Erasca (NASDAQ:ERAS) In A Good Position To Invest In Growth?finance.yahoo.com - January 9 at 8:28 AMErasca Stock (NASDAQ:ERAS), Analyst Ratings, Price Targets, Predictionsbenzinga.com - January 7 at 3:13 PMB of A Securities Downgrades Erasca (ERAS)msn.com - January 6 at 2:43 AMErasca to Present at the 42nd Annual J.P. Morgan Healthcare Conferencefinance.yahoo.com - January 3 at 12:27 PMShort Interest in Erasca, Inc. (NASDAQ:ERAS) Grows By 21.4%marketbeat.com - January 2 at 7:44 PMStrong Buy Rating for Erasca’s Stock on FDA Fast Track Designation and Market Expansion Potentialmarkets.businessinsider.com - December 13 at 10:10 PMErasca Co-Founder Acquires 3.2% More Stockfinance.yahoo.com - December 13 at 7:08 AMErasca: FDA Grants Fast Track Designation To Naporafenib In Combination With Trametinibmarkets.businessinsider.com - December 11 at 1:12 PMErasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanomafinance.yahoo.com - December 11 at 8:12 AMErasca director Alexander Casdin discloses purchase of 30K sharesmsn.com - December 7 at 12:05 PMErasca CEO Lim buys stock worth $1.7M - filingmsn.com - December 7 at 12:05 PMErasca, Inc.: Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runwayfinanznachrichten.de - November 28 at 3:47 PMErasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runwayfinance.yahoo.com - November 28 at 10:47 AMErasca GAAP EPS of -$0.20 beats by $0.01msn.com - November 9 at 7:43 PMErasca Reports Third Quarter 2023 Financial Results and Business Updatesfinance.yahoo.com - November 9 at 7:43 PMErasca Inc ERASmorningstar.com - November 8 at 9:14 AMWith 31% ownership, Erasca, Inc. (NASDAQ:ERAS) has piqued the interest of institutional investorsfinance.yahoo.com - November 8 at 9:14 AMErasca to Present at Upcoming Investor Conferences in Novemberfinance.yahoo.com - November 8 at 9:14 AMInsider Spends US$2.0m Buying More Shares In Erascafinance.yahoo.com - October 12 at 10:32 AMHC Wainwright & Co. Initiates Coverage of Erasca (ERAS) with Buy Recommendationmsn.com - October 12 at 5:32 AMErasca Shares Rise 14%, Chairman Buys 1M Sharesmarketwatch.com - October 10 at 9:15 PMWhy Shares of Erasca Are Jumping Tuesdayfinance.yahoo.com - October 10 at 4:15 PMErasca to Present at the Cantor Global Healthcare Conferencefinance.yahoo.com - September 19 at 8:36 AMErasca, Inc. (ERAS)finance.yahoo.com - September 9 at 2:05 PMErasca to Present at the Morgan Stanley 21st Annual Global Healthcare Conferencefinance.yahoo.com - September 5 at 6:53 PMErasca doses first patient in solid tumours combo therapy trialmsn.com - August 30 at 9:28 AM Get Erasca News Delivered to You Automatically Sign up to receive the latest news and ratings for ERAS and its competitors with MarketBeat's FREE daily newsletter. Email Address Mysterious Gold Leverage Just Announced (Ad)World's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers. Find out what it is and see how you can get in with just a few dollars. ERAS Media Mentions By Week ERAS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ERAS News Sentiment▼0.750.44▲Average Medical News Sentiment ERAS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ERAS Articles This Week▼21▲ERAS Articles Average Week Get Erasca News Delivered to You Automatically Sign up to receive the latest news and ratings for ERAS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Akebia Therapeutics News CorMedix News Verrica Pharmaceuticals News Inozyme Pharma News XOMA News RAPT Therapeutics News Terns Pharmaceuticals News Aquestive Therapeutics News Kamada News Black Diamond Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ERAS) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street Star“The Biggest Bubble of All Time” – Here’s What to Do.Chaikin Analyticstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBetter than Bitcoin? The Biotech Stock with 46,751% PotentialBehind the MarketsGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchThese AI trades triggered this morning (545% return)Prosper Trading AcademyBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Erasca, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
